Bristol Myers Squibb · 3 months ago
Principal Scientist, In Vivo Pharmacology, Oncology Discovery Biology
Cambridge Crossing - MA - US
Full-time
Onsite
Senior Level, Lead/Staff
$156K/yr - $189K/yr
4+ years expBristol Myers Squibb is a leading biopharmaceutical company focused on discovering and developing innovative medicines. The Principal Scientist role within Oncology Discovery Pharmacology involves leading in vivo strategies for drug discovery programs, utilizing scientific expertise to drive projects from concept to clinical development.
BiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Function as Pharmacology lead as well as provide support for T cell engager drug discovery programs. Working closely with project teams and key stakeholders, lead the development of in vivo strategies from target concept to Proof of Concept in patients, applying scientific and technical skills and functional knowledge to complex projects
Demonstrate critical thinking to address project challenges and independently drive the program forward with solution-oriented mindset
Characterize drug candidates in vivo as part of the lead selection process, utilizing strong foundational knowledge of building PK, PD, BioD and efficacy relationship in vivo and employ innovative approaches and novel technologies to advance research molecules towards development candidate selection and IND
Identify and develop state of the art in vivo models, experimental protocols and relevant assays. Work with cross-functional teams participate in development and implementation of program strategy, including integrating in vivo pharmacology strategy with toxicology and translational strategies to support regulatory filings
Design, independently execute and deliver experiments with comprehensive high quality data sets to drive decision making. Interpret results of complex experiments. Use relevant information, technology and resources, contributing to complex team problem resolution and goals. Proactively foster relationships across disciplines to facilitate decision making process
Participates in the decision-making process for completion of team goals and communicates program strategy and timelines to Project teams. Prepare and present comprehensive technical or project updates in team meetings and other forums
Leads initiatives related to development of new approaches / technologies within T-Cell engager strategy. Encourages use of experimental / innovative approaches within group
Qualification
Required
Bachelor's Degree with 8+ years of academic and/or industry experience
Master's Degree with 6+ years of academic and/or industry experience
Ph.D. or equivalent advanced degree in the Life Sciences with 4+ years of academic and/or industry experience
Preferred
PhD immunology, cancer biology or relevant biological science with 4+ years of relevant industry experience in in vivo pharmacology and a comprehensive expertise in oncology drug discovery, T cell biology and immuno-oncology
Industry experience with a proven track record of independently driving in vivo strategy for immune cell engagers, including CD3 T cell engagers as cancer therapeutic
Demonstrated ability to independently develop focused in vivo strategies and utilizing PK/PD/efficacy data to drive discovery, optimization, and characterization of CD3 T-cell engagers is required
Demonstrated leadership in developing and deploying novel in vivo models to enable immune cell engager, including T-cell engagers, drug discovery and translational research is required
Hands-on experience using various cell line and PDX mouse models, humanized mouse models, admixture xenografts, orthotopic models to execute in vivo workflows enabling candidate selection for early clinical development is highly desired
Demonstrated expertise in utilizing relevant pharmacodynamic assays such as MSD ELISAs, Luminex and immune profiling by flow cytometry. Proficient in developing FACS panels, executing ex-vivo profiling approaches and analyzing FACS datasets
Familiar with PET/CT, IVIS and other novel imaging approaches, data analysis methods for evaluating Biodistribution of biological modalities
Excellent interpersonal and communication skills with the ability to interact effectively with internal and external colleagues are required
Competitive candidates are expected to have a strong track record of independent and innovative research
Benefits
Health Coverage: Medical, pharmacy, dental, and vision care.
Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP).
Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support.
Paid Time Off
US Exempt Employees: flexible time off (unlimited, with manager approval, 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees)
Phoenix, AZ, Puerto Rico and Rayzebio Exempt, Non-Exempt, Hourly Employees: 160 hours annual paid vacation for new hires with manager approval, 11 national holidays, and 3 optional holidays
Up to 2 paid volunteer days per year
Summer hours flexibility
Leaves of absence for medical, personal, parental, caregiver, bereavement, and military needs
An annual Global Shutdown between Christmas and New Years Day.
Company
Bristol Myers Squibb
At Bristol Myers Squibb, we work every day to transform patients’ lives through science.
10001+ employees
H1B Sponsorship
Bristol Myers Squibb has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (247)
2024 (278)
2023 (231)
2022 (180)
2021 (181)
2020 (169)
Funding
Current Stage
Public CompanyTotal Funding
$29.32BKey Investors
Venrock
2025-11-05Post Ipo Debt· $5.74B
2024-02-14Post Ipo Debt· $13B
2023-10-30Post Ipo Debt· $4.5B
Leadership Team
Charles Bancroft
CFO
Cristian Massacesi
Executive Vice President, Chief Medical Officer and Head of Development
Recent News
2026-01-09
2026-01-08
2026-01-07
Company data provided by crunchbase